How GLP-1 drugs like Ozempic and Wegovy affect risk of 175 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.
Massive new study finds drugs like Ozempic affect 175 conditions — including a few surprises
A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — and even some new potential upsides.
GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
Not just weight loss, GLP-1 drugs like Ozempic can help with 175 conditions; says groundbreaking study
A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond their primary uses. This
Ozempic and Other GLP-1s May Have Broader Health Benefits but Greater Risks
Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a risk to other vital organs.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
What can’t GLP-1s do? Study maps benefits while warning of uncommon risks
GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes. Widely prescribed and wildly
Landmark Study Reveals New Benefits and Risks of Obesity Drugs Like Ozempic
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss.
Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind
Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.
Ozempic can lower chances of multiple health conditions but comes with risks, study finds
Ozempic, Wegovy, Zepbound and other drugs often used for weight loss can help lower the risk of a wide range of health conditions, according to a new study. But the drugs also pose certain risks. Kyle Benning explains.
Ozempic May Lower Your Dementia Risk, New Study Suggests. A Neurologist Explains The Potential Link
Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially ...
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Ozempic May Damage Vital Organs, Study Finds
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Hosted on MSN6d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Employee Benefit News6d
A guide to GLP-1 adoption: How employers can add this benefit in 2025
While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...